Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

12:30
10/21/18
10/21
12:30
10/21/18
12:30

Opdivo, Yervoy combo shows promising results in advanced form of bladder cancer

Bristol-Myers Squibb announced follow-up data evaluating Opdivo monotherapy and Opdivo in combination with Yervoy in patients with platinum-pretreated metastatic urothelial carcinoma. Results from the Phase 1/2 CheckMate -032 trial showed that patients who received the combination of Opdivo 1 mg/kg plus Yervoy 3 mg/kg experienced a higher objective response rate compared to those who received Opdivo 3 mg/kg plus Yervoy 1 mg/kg or Opdivo alone. Patients in the study were heavily pretreated, with most receiving at least two prior treatment regimens. At a minimum follow-up of 7.9 months for the expanded cohort of patients receiving O1:Y3, the ORR was 38%. For patients receiving O3:Y1, at a minimum follow-up of 38.8 months the ORR was 27%, and for patients receiving Opdivo alone, at a minimum follow-up of 37.7 months the ORR was 26%. Median progression-free survival and overall survival, secondary endpoints in the study, were numerically longer in the O1:Y3 treatment cohort compared to the O3:Y1 and Opdivo monotherapy cohorts. The overall safety profile was consistent with prior studies of Opdivo in combination with Yervoy with these dosing schedules. Grade 3 or 4 treatment-related adverse events occurred in 27%, 31% and 39% of patients treated with Opdivo monotherapy, O3:Y1 and O1:Y3, respectively; grade 5 TRAEs were observed in one patient each in the Opdivo monotherapy and O3:Y1 groups; no grade 5 TRAEs were observed in the O1:Y3 group. The combination of Opdivo plus Yervoy was also well tolerated, with 13% discontinuation rate due to TRAEs in the O1:Y3 group and 13% discontinuation rate in the O3:Y1 group. The discontinuation rate due to TRAEs in the Opdivo monotherapy group was 4%.

  • 22

    Oct

  • 25

    Oct

  • 29

    Oct

  • 07

    Nov

BMY Bristol-Myers
$54.31

-1.7 (-3.04%)

09/06/18
MSCO
09/06/18
NO CHANGE
Target $63
MSCO
Equal Weight
Bristol-Myers' TYK2 inhibitor may be underappreciated asset, says Morgan Stanley
Morgan Stanley analyst David Risinger said that Phase 2 data on Bristol-Myers' oral TYK2 inhibitor BMS-986165 will be presented at the EADV meeting on Wednesday September 12, adding that it could be an underappreciated asset if it offers better efficacy than other oral drugs and is safer. To his knowledge, no JAK inhibitors are currently being developed for psoriasis, Risinger noted. The analyst, who said 986165 "theoretically has blockbuster potential," maintains an Equal Weight rating on Bristol shares as further Opdivo lung newsflow is awaited.
09/12/18
FBCO
09/12/18
NO CHANGE
FBCO
Neutral
Bristol-Myers' TYK2 efficacy looks better than Otezla, says Credit Suisse
After Bristol-Myers (BMY) presented Phase 2 data for its oral TYK2 inhibitor, BMS-986165, in moderate-to-severe psoriasis at the EAVD meeting, Credit Suisse analyst Vamil Divan said he believes the "robust" data are very encouraging for the ongoing Phase 3 studies. BMS-986165 achieved PASI 75 response rates that are better than what was demonstrated by Celgene's (CELG) Otezla and the safety profile "appears reasonable," Divan tells investors. While BMS-986165 could be highly competitive clinically against other oral treatments, the crowded psoriasis market remains a tough one for new products, added the analyst, who keeps a Neutral rating on Bristol-Myers shares.
10/08/18
GUGG
10/08/18
INITIATION
Target $70
GUGG
Neutral
Bristol-Myers initiated with a Neutral at Guggenheim
Guggenheim analyst Seamus Fernandez started Bristol-Myers with a Neutral rating and $70 price target, contending that near-term Opdivo catalysts are largely in the stock. He sees the risk-reward as being balanced ahead of several trial read outs in 2019 from Bristol and its competitors, Fernandez added.
10/16/18
WELS
10/16/18
NO CHANGE
WELS
Drug price in ads not impactful, may cause confusion, says Wells Fargo
Wells Fargo analyst David Maris acknowledges that the U.S. Department of Health and Human Services' proposal to include drug prices in advertisements has a "noble goal" of making drugs more affordable and keeping patients well informed. However, given how different list prices are relative to out of pocket costs, "one must ask if this is increasing transparency or likely going to lead to more confusion," he contends. The analyst also believes that the unintended consequence could be worse care, while noting that the drug price information will likely fall into the category of the side effect information in drug ads currently, tuned out by many and will have no material impact. While he supports the idea of increased transparency, Maris wonders whether the potential benefit is not outweighed by the potential negative for the most vulnerable. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

TODAY'S FREE FLY STORIES

HYMTF

Hyundai Motor

$0.00

(0.00%)

21:09
03/21/19
03/21
21:09
03/21/19
21:09
Periodicals
Breaking Periodicals news story on Hyundai Motor »

Elliott Management loses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMTS

Sierra Metals

$1.64

0.05 (3.14%)

21:01
03/21/19
03/21
21:01
03/21/19
21:01
Hot Stocks
Sierra Metals announces 66% of Yauricocha Mine workers waged illegal strike »

Sierra Metals announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

LGF.B

Lionsgate

$15.17

0.4 (2.71%)

, NFLX

Netflix

$378.09

2.94 (0.78%)

20:32
03/21/19
03/21
20:32
03/21/19
20:32
Recommendations
Lionsgate, Netflix, Apple, Spotify, Roku analyst commentary at SunTrust »

Apple event may be…

LGF.B

Lionsgate

$15.17

0.4 (2.71%)

NFLX

Netflix

$378.09

2.94 (0.78%)

AAPL

Apple

$195.07

6.93 (3.68%)

SPOT

Spotify

$144.04

-0.01 (-0.01%)

ROKU

Roku

$66.82

1.86 (2.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

TSLA

Tesla

$274.10

0.6 (0.22%)

20:13
03/21/19
03/21
20:13
03/21/19
20:13
Hot Stocks
End of Tesla's referral program reduced costs, allowed to pass on savings »

In its blog, Tesla…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSBC

HSBC

$41.07

-0.16 (-0.39%)

, BLK

BlackRock

$430.32

0.35 (0.08%)

19:44
03/21/19
03/21
19:44
03/21/19
19:44
Periodicals
Breaking Periodicals news story on HSBC, BlackRock »

HSBC reaches deal to use…

HSBC

HSBC

$41.07

-0.16 (-0.39%)

BLK

BlackRock

$430.32

0.35 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

UBER

Uber

$0.00

(0.00%)

, ICE

IntercontinentalExchange

$73.36

0.15 (0.20%)

19:21
03/21/19
03/21
19:21
03/21/19
19:21
Periodicals
Uber selects NYSE for 2019 IPO, Bloomberg reports »

Uber (UBER) has picked…

UBER

Uber

$0.00

(0.00%)

ICE

IntercontinentalExchange

$73.36

0.15 (0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 17

    May

  • 28

    May

PIN

Pinterest

$25.63

-0.07 (-0.27%)

19:18
03/21/19
03/21
19:18
03/21/19
19:18
Periodicals
Pinterest moves up IPO timing, seeks to list shares on NYSE in April, WSJ says »

Pinterest has moved up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TAP

Molson Coors

$60.80

1.04 (1.74%)

, BUD

AB InBev

$83.94

0.52 (0.62%)

18:57
03/21/19
03/21
18:57
03/21/19
18:57
Periodicals
MillerCoors sues AB InBev over corn syrup claims, WSJ reports »

MillerCoors, a subsidiary…

TAP

Molson Coors

$60.80

1.04 (1.74%)

BUD

AB InBev

$83.94

0.52 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

OSS

One Stop Systems

$2.52

(0.00%)

, AMRN

Amarin

$18.77

-0.24 (-1.26%)

18:40
03/21/19
03/21
18:40
03/21/19
18:40
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: One…

OSS

One Stop Systems

$2.52

(0.00%)

AMRN

Amarin

$18.77

-0.24 (-1.26%)

GME

GameStop

$10.54

0.06 (0.57%)

DLNG

Dynagas LNG

$2.61

0.025 (0.97%)

ZUO

Zuora

$24.34

0.62 (2.61%)

CAL

Caleres

$25.75

-0.08 (-0.31%)

OPNT

Opiant Pharmaceuticals

$14.00

0.5 (3.70%)

NKE

Nike

$88.05

1.3597 (1.57%)

CTAS

Cintas

$208.00

2.78 (1.35%)

CNAT

Conatus

$2.91

0.02 (0.69%)

GG

Goldcorp

$11.17

0.13 (1.18%)

NEM

Newmont Mining

$34.32

0.44 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

  • 22

    Mar

  • 25

    Mar

  • 02

    Apr

  • 04

    Apr

  • 04

    Apr

  • 11

    Apr

  • 16

    Apr

  • 23

    Apr

UBER

Uber

$0.00

(0.00%)

, ICE

IntercontinentalExchange

$73.36

0.15 (0.20%)

18:40
03/21/19
03/21
18:40
03/21/19
18:40
Periodicals
Uber selects NYSE for 2019 IPO, Bloomberg reports »

Uber (UBER) has picked…

UBER

Uber

$0.00

(0.00%)

ICE

IntercontinentalExchange

$73.36

0.15 (0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 17

    May

  • 28

    May

CVS

CVS Health

$57.40

1.23 (2.19%)

18:34
03/21/19
03/21
18:34
03/21/19
18:34
Hot Stocks
CVS Health CEO: Off to great start with Aetna integration »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$284.63

3.19 (1.13%)

18:30
03/21/19
03/21
18:30
03/21/19
18:30
Periodicals
EU to offer U.K. Brexit negotiating period extension, Reuters says »

The EU plans to grant the…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$284.63

3.19 (1.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOK

Nokia

$6.26

-0.03 (-0.48%)

18:20
03/21/19
03/21
18:20
03/21/19
18:20
Periodicals
Nokia not planning to take on new business in Iran in 2019, Reuters says »

Nokia said it does not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

DNR

Denbury Resources

$1.95

0.06 (3.17%)

, PVAC

Penn Virginia

$54.29

1.74 (3.31%)

18:17
03/21/19
03/21
18:17
03/21/19
18:17
Hot Stocks
Denbury Resources: Penn Virginia deal was unlikely to receive majority approval »

Chris Kendall,…

DNR

Denbury Resources

$1.95

0.06 (3.17%)

PVAC

Penn Virginia

$54.29

1.74 (3.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

IMMP

Immutep

$2.40

-0.095 (-3.82%)

18:11
03/21/19
03/21
18:11
03/21/19
18:11
Hot Stocks
Immutep announces U.S. patent for Eftilagimod Alpha in cancer »

Immutep Limited is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PVAC

Penn Virginia

$54.29

1.74 (3.31%)

, DNR

Denbury Resources

$1.95

0.06 (3.17%)

18:08
03/21/19
03/21
18:08
03/21/19
18:08
Hot Stocks
Penn Virginia, Denbury Resources mutually agree to terminate merger pact »

Penn Virginia (PVAC)…

PVAC

Penn Virginia

$54.29

1.74 (3.31%)

DNR

Denbury Resources

$1.95

0.06 (3.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

LLL

L3 Technologies

$208.75

1.535 (0.74%)

17:44
03/21/19
03/21
17:44
03/21/19
17:44
Hot Stocks
L3 Technologies awarded $131.78M Air Force contract »

L3 Technologies has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Apr

  • 01

    May

GM

General Motors

$37.35

0.35 (0.95%)

17:42
03/21/19
03/21
17:42
03/21/19
17:42
Periodicals
GM to invest $300M in Orion EV/AV factory, Reuters reports »

General Motors intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 30

    Apr

GD

General Dynamics

$169.81

1.21 (0.72%)

17:42
03/21/19
03/21
17:42
03/21/19
17:42
Hot Stocks
General Dynamics awarded $465.15M Navy contract for CVN shipyard availabilities »

General Dynamics has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

NKE

Nike

$88.05

1.3597 (1.57%)

17:41
03/21/19
03/21
17:41
03/21/19
17:41
Earnings
Breaking Earnings news story on Nike »

Nike sees FY20 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 04

    Apr

  • 04

    Apr

NKE

Nike

$88.05

1.3597 (1.57%)

17:39
03/21/19
03/21
17:39
03/21/19
17:39
Earnings
Nike sees Q4 revenue growth in high single-digit range, consensus $10.38B »

Sees Q4 gross margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 04

    Apr

  • 04

    Apr

NKE

Nike

$88.05

1.3597 (1.57%)

17:36
03/21/19
03/21
17:36
03/21/19
17:36
Hot Stocks
Nike says it is not taking China momentum for granted »

Says leveraging the power…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 04

    Apr

  • 04

    Apr

LOV

Spark Networks

$11.29

(0.00%)

17:34
03/21/19
03/21
17:34
03/21/19
17:34
Hot Stocks
Spark Networks to acquire Zoosk, sees adjusted EBITDA to exceed $50M in 2020 »

Spark Networks announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACA

Arcosa

$29.74

-0.16 (-0.54%)

17:29
03/21/19
03/21
17:29
03/21/19
17:29
Initiation
Arcosa initiated at DA Davidson »

Arcosa initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$138.09

0.86 (0.63%)

17:24
03/21/19
03/21
17:24
03/21/19
17:24
Hot Stocks
Johnson & Johnson sees Q1 charge of about $700M related to AL-8176 »

On March 21, Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Apr

  • 25

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.